Our top pick for
Pliant Therapeutics, Inc is a biotechnology business based in the US. Pliant Therapeutics shares (PLRX) are listed on the NASDAQ and all prices are listed in US Dollars. Pliant Therapeutics employs 90 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$30.06|
|52-week range||$19.43 - $43.92|
|50-day moving average||$28.09|
|200-day moving average||$31.23|
|Wall St. target price||$51.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.27|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-24)||N/A|
|1 month (2021-07-02)||6.90%|
|3 months (2021-05-04)||-13.99%|
|6 months (2021-01-31)||N/A|
|1 year (2020-07-31)||N/A|
|2 years (2019-07-31)||N/A|
|3 years (2018-07-31)||N/A|
|5 years (2016-07-31)||N/A|
Valuing Pliant Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pliant Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pliant Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $20.8 million.
The EBITDA is a measure of a Pliant Therapeutics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$15.1 million|
|Gross profit TTM||$41.8 million|
|Return on assets TTM||-20.57%|
|Return on equity TTM||-34.46%|
|Market capitalisation||$904.4 million|
TTM: trailing 12 months
There are currently 1.9 million Pliant Therapeutics shares held short by investors – that's known as Pliant Therapeutics's "short interest". This figure is 13.5% up from 1.7 million last month.
There are a few different ways that this level of interest in shorting Pliant Therapeutics shares can be evaluated.
Pliant Therapeutics's "short interest ratio" (SIR) is the quantity of Pliant Therapeutics shares currently shorted divided by the average quantity of Pliant Therapeutics shares traded daily (recently around 130851.27674258). Pliant Therapeutics's SIR currently stands at 14.49. In other words for every 100,000 Pliant Therapeutics shares traded daily on the market, roughly 14490 shares are currently held short.
However Pliant Therapeutics's short interest can also be evaluated against the total number of Pliant Therapeutics shares, or, against the total number of tradable Pliant Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pliant Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Pliant Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0998% of the tradable shares (for every 100,000 tradable Pliant Therapeutics shares, roughly 100 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Pliant Therapeutics.
Find out more about how you can short Pliant Therapeutics stock.
We're not expecting Pliant Therapeutics to pay a dividend over the next 12 months.
Pliant Therapeutics, Inc. , a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in Phase II single ascending dose/multiple ascending dose trails and completed Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.